2-pyrrolino-dox has been researched along with Experimental Mammary Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Groot, K; Halmos, G; Nagy, A; Schally, AV; Szepeshazi, K | 1 |
Nagy, A; Schally, AV; Szepeshazi, K | 1 |
2 other study(ies) available for 2-pyrrolino-dox and Experimental Mammary Neoplasms
Article | Year |
---|---|
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Division; Cell Survival; DNA, Neoplasm; Doxorubicin; Estrogens; Female; Gonadotropin-Releasing Hormone; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Hormone-Dependent; Pyrroles; Receptors, LHRH | 1997 |
Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
Topics: Animals; Antineoplastic Agents; Cell Division; Doxorubicin; Drug Delivery Systems; Estrogens; Female; Gonadotropin-Releasing Hormone; Growth Inhibitors; Injections, Intravenous; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Hormone-Dependent; Pyrroles | 1999 |